Who makes GSK2894512 Topical Cream?

GSK2894512 Topical Cream is developed by GlaxoSmithKline.

What development phase is GSK2894512 Topical Cream in?

GSK2894512 Topical Cream is in Phase 1.

Last reviewed 2026-05-14 · How we verify

GSK2894512 Topical Cream

GlaxoSmithKline · Phase 1 active Small molecule

At a glance

Generic name	GSK2894512 Topical Cream
Sponsor	GlaxoSmithKline
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

GSK2894512 Vehicle-Controlled Study for Adult Plaque Psoriasis (PHASE3)
A Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of GSK2894512 in Healthy Adult Subjects (PHASE1)
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD) (PHASE2)
A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis (PHASE2)
A Study to Evaluate the Irritation Potential of GSK2894512 Cream on Skin in Healthy Subjects (PHASE1)
Pharmacokinetic Study of Topical GSK2894512 Cream (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

GSK2894512 Topical Cream CI brief — competitive landscape report
GSK2894512 Topical Cream updates RSS · CI watch RSS
GlaxoSmithKline portfolio CI